Loxo Oncology, Inc. (LOXO) [Rocket]

In millions, except per share items	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13
	10-K	10-K	10-K	10-K	10-K
Revenues	21.3	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	21.3	0.0	0.0	0.0	0.0
Gross margin	100.0%
Selling, general and administrative [+]	33.7	14.9	10.5	6.2
General and administrative	33.7	14.9	10.5	6.2	0.0
Research and development	140.0	58.3	14.0	6.9
Other operating expenses			11.6	7.6
EBITDA [+]	-152.2	-72.6	-35.7	-20.7
EBITDA growth	109.7%	103.5%	72.6%
EBITDA margin	-714.5%
Depreciation	0.1	0.1	0.0	0.0
EBITA	-152.3	-72.7	-35.7	-20.7	0.0
EBITA margin	-715.1%
Amortization of intangibles	0.1	0.5	0.4	0.0
EBIT [+]	-152.4	-73.2	-36.1	-20.7	0.0
EBIT growth	108.3%	102.8%	74.4%
EBIT margin	-715.5%
Interest income	3.5	0.8	0.2	0.0
Interest income	3.5	0.8	0.2	0.0
Other income (expense), net				0.0
Pre-tax income	-148.9	-72.4	-35.9	-20.7	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.1%
Net income	-148.9	-72.4	-35.9	-20.7	0.0
Net margin	-698.9%

Basic EPS [+]	($5.31)	($3.46)	($2.12)	($3.06)
Growth	53.3%	63.1%	-30.5%
Diluted EPS [+]	($5.31)	($3.46)	($2.12)	($3.06)
Growth	53.3%	63.1%	-30.5%

Shares outstanding (basic) [+]	28.0	20.9	16.9	6.8
Growth	34.1%	23.7%	149.4%
Shares outstanding (diluted) [+]	28.0	20.9	16.9	6.8
Growth	34.1%	23.7%	149.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.